Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium
Heather Callaway, Kathryn M. Hastie, Sharon L. Schendel, et al.
Cell Reports (2023) Vol. 42, Iss. 1, pp. 112014-112014
Open Access | Times Cited: 22

Showing 22 citing articles:

IgG3 subclass antibodies recognize antigenically drifted influenza viruses and SARS-CoV-2 variants through efficient bivalent binding
Marcus J. Bolton, Jefferson Santos, Claudia P. Arevalo, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 35
Open Access | Times Cited: 17
Longitudinal Assessment of BNT162b2- and mRNA-1273-Induced Anti-SARS-CoV-2 Spike IgG Levels and Avidity Following Three Doses of Vaccination
Jimmie Bullock, Thomas E. Hickey, Troy J. Kemp, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 516-516
Open Access | Times Cited: 5
Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection
Lei Yu, Yajie Wang, Yuanchen Liu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
The molecular reach of antibodies crucially underpins their viral neutralisation capacity
Anna Huhn, Daniel A. Nissley, Daniel B. Wilson, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection
Yu Lei, Yajie Wang, Yuanchen Liu, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology
Daniel N. Streblow, Alec J. Hirsch, Jeffrey J. Stanton, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition
Roi Asor, Anna Olerinyova, Sean A. Burnap, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 40
Open Access | Times Cited: 3
Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5
Kevin C. Entzminger, Jonathan K. Fleming, Paul D. Entzminger, et al.
Antibody Therapeutics (2023) Vol. 6, Iss. 2, pp. 108-118
Open Access | Times Cited: 7
Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence
Kathryn M. Hastie, Xiaoying Yu, Fernanda Ana‐Sosa‐Batiz, et al.
Cell Reports (2023) Vol. 42, Iss. 5, pp. 112421-112421
Open Access | Times Cited: 6
Multimodal, broadly neutralizing antibodies against SARS-CoV-2 identified by high-throughput native pairing of BCRs from bulk B cells
Gladys J. Keitany, Benjamin E. Rubin, Meghan Garrett, et al.
Cell chemical biology (2023) Vol. 30, Iss. 11, pp. 1377-1389.e8
Open Access | Times Cited: 6
Variant-specific humoral immune response to SARS-CoV-2 escape mutants arising in clinically severe, prolonged infection
Theresa Günther, Michael Schöfbänker, Eva U. Lorentzen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Discordant Antigenic Properties of Soluble and Virion SARS-CoV-2 Spike Proteins
Sameer Kumar, Souradip Dasgupta, Mohammad M. Sajadi, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 407-407
Open Access | Times Cited: 1
Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including XBB.1.5 and BQ.1.1
Kevin C. Entzminger, Jonathan K. Fleming, Paul D. Entzminger, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis
Tanaporn Meejun, Karan Srisurapanont, Kasama Manothummetha, et al.
Blood Advances (2023) Vol. 7, Iss. 18, pp. 5624-5636
Open Access | Times Cited: 3
Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19
Garyphallia Poulakou, Pierre‐Joseph Royer, Nikolay Evgeniev, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection
Michael Schoefbaenker, Theresa Günther, Eva U. Lorentzen, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 10, pp. e1012624-e1012624
Open Access
Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly Administered Vaccines
Anthony M. Marchese, Louis Fries, Hadi Beyhaghi, et al.
Journal of Infection (2024), pp. 106317-106317
Open Access
Distinct Binding Modes of Inter-Spike Cross-Linking Suggest a Supplementary Mechanism for SARS-CoV-2 Antibody Neutralization
Xuanyu Nan, Yujie Li, Rui Zhang, et al.
(2024)
Closed Access
Exploring distinct modes of inter-spike cross-linking for enhanced neutralization by SARS-CoV-2 antibodies
Xuanyu Nan, Yujie Li, Rui Zhang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access
Forty years of HIV research inspires the development of SARS-CoV-2 therapy
Roberto Patarca, William A. Haseltine
Journal of Molecular Cell Biology (2023) Vol. 15, Iss. 10
Open Access | Times Cited: 1
Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can retain functional binding affinity to spike variants
Kan Li, Richard H.C. Huntwork, Gillian Q. Horn, et al.
Journal of Virology (2023) Vol. 97, Iss. 12
Open Access | Times Cited: 1
XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants
Garyphallia Poulakou, Pierre‐Joseph Royer, Nikolai Evgeniev, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top